On November 12, BEONE MEDICINES rose 3.1% in regular trading, with shares trading at HK$259.4 and turnover of HK$334 million.
The immediate catalyst was a disclosed custody-position change: 130 million shares were deposited into Citibank, involving a holding ratio change of 8.46%, while the total deposited position market value reached HK$32.786 billion, or 8.43% of shares.
Background fundamentals remained supportive. The company recently reported first-three-quarter revenue of RMB34.993 billion, up 26.81% year over year, and net profit attributable to shareholders of RMB6.055 billion, up 431.81%. It also raised full-year revenue guidance for the third time to RMB46.3 billion to RMB47.0 billion, reinforcing expectations for continued commercialization ramp-up and margin improvement. Broker research also turned more constructive after the quarterly release, with target prices revised upward.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments